Champions Oncology, Inc.
CSBR
$7.05
-$0.02-0.28%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.42M | 56.88M | 56.94M | 58.59M | 53.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.42M | 56.88M | 56.94M | 58.59M | 53.57M |
| Cost of Revenue | 29.15M | 29.31M | 28.39M | 28.37M | 29.60M |
| Gross Profit | 29.28M | 27.57M | 28.56M | 30.22M | 23.97M |
| SG&A Expenses | 18.44M | 17.10M | 16.89M | 16.59M | 16.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.96M | 53.87M | 52.10M | 51.87M | 53.92M |
| Operating Income | 2.46M | 3.01M | 4.85M | 6.72M | -352.00K |
| Income Before Tax | 2.36M | 2.84M | 4.63M | 6.40M | -636.00K |
| Income Tax Expenses | -74.00K | -81.00K | -74.00K | -26.00K | -38.00K |
| Earnings from Continuing Operations | 2.43 | 2.92 | 4.70 | 6.43 | -0.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 61.00K | 30.00K | -- | -- | -- |
| Net Income | 2.49M | 2.95M | 4.70M | 6.43M | -598.00K |
| EBIT | 2.46M | 3.01M | 4.85M | 6.72M | -352.00K |
| EBITDA | 3.97M | 4.56M | 6.49M | 8.43M | 1.43M |
| EPS Basic | 0.18 | 0.22 | 0.34 | 0.47 | -0.04 |
| Normalized Basic EPS | 0.13 | 0.15 | 0.23 | 0.31 | -0.01 |
| EPS Diluted | 0.16 | 0.20 | 0.32 | 0.44 | -0.06 |
| Normalized Diluted EPS | 0.12 | 0.14 | 0.21 | 0.30 | -0.01 |
| Average Basic Shares Outstanding | 55.03M | 54.84M | 54.64M | 54.48M | 54.38M |
| Average Diluted Shares Outstanding | 56.36M | 55.92M | 56.18M | 56.02M | 55.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |